Metabolic profiling of glioblastoma using advanced imaging techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to perform metabolic phenotyping of treatment-naïve and recurrent glioblastoma (GBM) using multitracer PET imaging with 18F-Fluciclovine and 18F-FDG, along with advanced MRI techniques. Participants will undergo dynamic PET/CT scans to evaluate the uptake of these tracers and will also have the option for additional MRI scans to assess glutamate and lactate levels. The goal is to compare imaging results with tumor tissue assays to better understand metabolic processes in GBM. This research could provide insights into tumor behavior and treatment responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants will be ≥ 18 years of age

Must meet the following criteria:

-Diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist.

OR

* New contrast-enhancing lesion or lesions showing increased enhancement (\>25%increase) in a patient with a historical diagnosis of glioblastoma (histologic or molecular proof) on standard MRI after completion of treatment
* Recommended for clinically indicated surgical resection
* Life expectancy of greater than 3 months in the opinion of an investigator or treating physician.
* Karnofsky performance status ≥ 60 per medical record review
* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
* Females who are pregnant or breastfeeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential prior to injection.
* Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
* Contraindications to MRI
* Only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study

Where it's running

• Hospital of the University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting
• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Ali Nabavizadeh, MD — University of Pensylvania
• Study coordinator: Leeanne Lezotte
• Email: leeanne.lezotte@pennmedicine.upenn.edu
• Phone: 8563643137

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing surgery and best treatment for recurrent glioblastoma

  This study is testing whether surgery or the best available treatment helps people with recurring glioblastoma feel better and live longer.

  Recruiting at 6 sites Erasmus Medical Center · San Francisco, California and 7 other locations · NCT06283927

• Resection techniques for recurrent glioblastoma

  This study is testing different methods of mapping the brain during surgery for recurring glioblastoma to see which one helps patients keep their movement and speech abilities while removing as much of the tumor as possible.

  Recruiting at 6 sites Erasmus Medical Center · San Francisco, California and 7 other locations · NCT06273176

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Sitagliptin plus bevacizumab for recurrent grade 4 glioma

  This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07541781

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Phase 1 safety and dose-finding of GLIX1 for adults with recurrent or progressive high-grade glioma

  This trial will test whether taking oral GLIX1 daily is safe, tolerable, and shows early anti-tumor activity in adults with recurrent or progressive high-grade glioma.

  Recruiting at 4 sites Phase 1 Tetragon Biosciences Ltd · Palo Alto, California and 3 other locations · NCT07464925

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.